Jain, Saundra
Gupta, Shaloo
Li, Vicky W.
Suthoff, Ellison
Arnaud, Alix
Article History
Received: 28 January 2022
Accepted: 25 July 2022
First Online: 11 August 2022
Declarations
:
: The study protocol and questionnaire were reviewed by the Pearl Institutional Review Board and granted exemption status. All research reported here was conducted in accordance with the Good Pharmacoepidemiology Practices (GPP) guidelines issued by the International Society for Pharmacoepidemiology (ISPE). All respondents provided informed consent prior to participating.
: Not applicable.
: SJ is an adjunct Clinical Affiliate, School of Nursing at University of Texas, Austin. SG and VWL are employees of Cerner Enviza. ES is an employee of Sage Therapeutics, Inc. AA is a former employee of Sage Therapeutics, Inc.